Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all lung cancer cases. Find out more about testing and treatment here.
Transforming the Treatment of Lung Fibrosis through Lung Repair and Regeneration
Matthew Thomas, Head of Immunology & Respiratory Research, Germany, describes how translational science approaches are informing our lung fibrosis research
Hope for the future of interstitial lung disease (ILD) care
Karen Moor, pulmonologist in training and post-doctoral researcher in interstitial lung diseases (ILDs), shares her advice for aspiring pulmonologists and her hopes for the future of ILD care.
Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
T-cell engagers: Reawakening T-cells to fight cancer
Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology, highlighting our T-cell engagers platform and how we are driving innovation to deliver meaningful advances to people with cancer.
From early stage discovery to clinical trials and approval, we’re Taking Cancer On. Click here to access the podcast homepage, where you will find all the available episodes.